Cargando…
P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431515/ http://dx.doi.org/10.1097/01.HS9.0000971160.69126.7e |
| _version_ | 1785091220393951232 |
|---|---|
| author | Dickinson, Michael Berkahn, Leanne Trotman, Judith Butler, Jason Neeson, Paul Bressel, Matthias Minson, Adrian |
| author_facet | Dickinson, Michael Berkahn, Leanne Trotman, Judith Butler, Jason Neeson, Paul Bressel, Matthias Minson, Adrian |
| author_sort | Dickinson, Michael |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431515 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104315152023-08-17 P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL. Dickinson, Michael Berkahn, Leanne Trotman, Judith Butler, Jason Neeson, Paul Bressel, Matthias Minson, Adrian Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431515/ http://dx.doi.org/10.1097/01.HS9.0000971160.69126.7e Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Dickinson, Michael Berkahn, Leanne Trotman, Judith Butler, Jason Neeson, Paul Bressel, Matthias Minson, Adrian P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL. |
| title | P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL. |
| title_full | P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL. |
| title_fullStr | P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL. |
| title_full_unstemmed | P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL. |
| title_short | P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL. |
| title_sort | p1066: pembrolizumab monotherapy as a first therapy for hodgkin lymphoma is deliverable in older or abvd ineligible patients, does not preclude subsequent therapy, and provides adequate survival. |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431515/ http://dx.doi.org/10.1097/01.HS9.0000971160.69126.7e |
| work_keys_str_mv | AT dickinsonmichael p1066pembrolizumabmonotherapyasafirsttherapyforhodgkinlymphomaisdeliverableinolderorabvdineligiblepatientsdoesnotprecludesubsequenttherapyandprovidesadequatesurvival AT berkahnleanne p1066pembrolizumabmonotherapyasafirsttherapyforhodgkinlymphomaisdeliverableinolderorabvdineligiblepatientsdoesnotprecludesubsequenttherapyandprovidesadequatesurvival AT trotmanjudith p1066pembrolizumabmonotherapyasafirsttherapyforhodgkinlymphomaisdeliverableinolderorabvdineligiblepatientsdoesnotprecludesubsequenttherapyandprovidesadequatesurvival AT butlerjason p1066pembrolizumabmonotherapyasafirsttherapyforhodgkinlymphomaisdeliverableinolderorabvdineligiblepatientsdoesnotprecludesubsequenttherapyandprovidesadequatesurvival AT neesonpaul p1066pembrolizumabmonotherapyasafirsttherapyforhodgkinlymphomaisdeliverableinolderorabvdineligiblepatientsdoesnotprecludesubsequenttherapyandprovidesadequatesurvival AT bresselmatthias p1066pembrolizumabmonotherapyasafirsttherapyforhodgkinlymphomaisdeliverableinolderorabvdineligiblepatientsdoesnotprecludesubsequenttherapyandprovidesadequatesurvival AT minsonadrian p1066pembrolizumabmonotherapyasafirsttherapyforhodgkinlymphomaisdeliverableinolderorabvdineligiblepatientsdoesnotprecludesubsequenttherapyandprovidesadequatesurvival |